| Patent application number | Description | Published |
|---|
| 20100029920 | METHOD FOR ASSESSING THE EFFECT OF A DRUG ON LONG TERM MEMORY FORMATION - Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed. | 02-04-2010 |
| 20100144614 | ALTERING MEMORY BY AFFECTING STAUFEN FUNCTION - The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or STAUFEN function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating staufen-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation associated with a defect in STAUFEN and methods for treating a defect in performance of a hippocampal-dependent cognitive task associated with a defect in STAUFEN. | 06-10-2010 |
| 20110044955 | ALTERING MEMORY BY AFFECTING STAUFEN - The present invention provides cell-based screening methods for identifying pharmaceutical agents which are capable of modulating (have the ability to modulate) STAUFEN function by screening for STAUFEN function. | 02-24-2011 |
| 20110105569 | PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT - The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors. | 05-05-2011 |
| 20110105570 | PHOSPHODIESESTERASE 4 INHIBITORS FOR THE TREATMENT OF A COGNITIVE DEFICIT - The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors. | 05-05-2011 |
| Patent application number | Description | Published |
|---|
| 20090022667 | METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 - The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function. | 01-22-2009 |
| 20090053140 | METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA) - The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under conditions sufficient to induce transcription dependent memory formation in a normal untreated animal; and (c) determining the level of transcription dependent memory formation induced by the training of the treated animal. The present invention provides methods of using small interfering PNAs (siRNA) in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term (LTM) memory, but not short-term memory (STM). | 02-26-2009 |
| 20100028839 | METHODS AND SYSTEMS FOR EVALUATING MEMORY AGENTS - The present invention provides methods and systems for identifying, evaluating, and testing various compounds as memory agents and regimens as training protocols related to memory enhancement and/or impairment. Such methods and systems may test any compounds or protocols, including the memory agents and training protocols described herein. The methods can comprise combining training protocols with the general administration of memory agents. In some embodiments, the present invention may involve identifying, selecting, testing, evaluating or assessing a compound as a drug candidate for a memory agent, for example, as one effective for enhancing or impairing memory. | 02-04-2010 |
| 20100285990 | NEURITE OUTGROWTH AS AN ASSAY FOR MEMORY ENHANCING COMPOUNDS - The disclosed invention relates to cell based screening assays that are useful to identify compounds that enhance memory in normal and memory impaired individuals. | 11-11-2010 |
| 20110076235 | GENES, METHODS, AND COMPOSITIONS RELATED TO NEUROGENESIS AND ITS MODULATION - The present disclosure provides methods for investigating neurogenesis, neural cell proliferation and differentiation. Specifically, the present disclosure relates to methods for identifying pharmaceutical agents capable of modulating neurogenesis and neural cell proliferation, methods of screening for genes that modulate neurogenesis and proliferation of neural progenitor cells, and methods of identifying pharmaceutical agents as candidate modulators of neurogenesis and neural proliferation or differentiation. The present disclosure also relates to methods for identifying pharmaceutical agents to characterize and modulate neurogenesis, pharmaceutical agents identified by such methods, methods for treating patients with such pharmaceutical agents, and compositions containing such pharmaceutical agents. Accordingly, the present methods enable elucidation of the mechanisms that control neurogenesis, brain development and function in healthy animals and in disorders of the nervous system. Furthermore, the present methods facilitate the development of compositions to prevent, improve or stabilize impaired neurogenesis in various nervous system disorders, including cognitive disorders. | 03-31-2011 |
| 20110093206 | METHODS, SYSTEMS, AND PRODUCTS FOR QUANTITATIVELY MEASURING THE DEGREE OF CONCORDANCE BETWEEN OR AMONG MICROARRAY PROBE LEVEL DATA SETS - Methods, systems and products are provided to quantitatively measure the degree of concordance between or among microarray probe level data sets. These can include the steps of evaluating outlier probe values, determine gene expression scores, evaluating the significant treatment effect for each gene expression score, and determining concordance between replicate data sets | 04-21-2011 |
